China Tian Yuan Healthcare Group Limited (0557) AI Stock Analysis

• Market Cap: HK$315.19M
• Dividend Yield: N/A
• Average Volume (3M): 11.87K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.57
• Revenue Growth: -40.65%
• EPS Growth: -121.13%
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 37
• Industry: Travel Lodging
• EPS (TTM): -0.07
• Shares Outstanding: 398,979,520
• 10 Day Avg. Volume: 24,600
• 30 Day Avg. Volume: 11,866
• PEG Ratio: N/A
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 22.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.00
• Price Target Upside: 26.58% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: HK$1.00 ▲(26.58%Upside)

The stock's overall score is primarily impacted by significant financial challenges and poor valuation metrics. While technical analysis shows a positive trend, it is insufficient to offset the negative financial performance and valuation concerns.

China Tian Yuan Healthcare Group Limited Business Overview & Revenue Model

Company Description

China Tian Yuan Healthcare Group Limited (0557) is a diversified investment holding company primarily engaged in healthcare and related services. The company operates through various segments including healthcare services, medical equipment distribution, and related investment activities. It aims to integrate healthcare resources and expand its presence in the healthcare sector across the region.

How the Company Makes Money

The company generates revenue through multiple streams, primarily focusing on healthcare services and the distribution of medical equipment. This includes income from hospital operations, diagnostic services, and the sale of medical devices. Additionally, the company engages in strategic investments and partnerships within the healthcare industry to enhance its service offerings and drive growth. Key revenue contributors include service fees from healthcare facilities, sales of medical products, and returns on healthcare-related investments.

China Tian Yuan Healthcare Group Limited Financial Statement Overview

Summary

The company is facing significant financial challenges with declining revenues and persistent losses impacting profitability. The balance sheet is stable with a strong equity position, but cash flow improvements are overshadowed by volatility and past inefficiencies.

Income Statement

The company has seen a consistent decline in revenue over the years, with significant negative figures in EBIT and net income indicating ongoing profitability issues. Gross profit margin is high but overshadowed by persistent losses, suggesting challenges in controlling operating expenses.

Balance Sheet

The company's debt-to-equity ratio is relatively low, indicating conservative leverage. However, the significant decline in stockholders' equity due to consistent losses raises concerns. The equity ratio remains strong, showing a robust capital structure despite financial challenges.

Cash Flow

Positive operating cash flow in recent years is a positive sign, suggesting some operational efficiency. However, free cash flow has been volatile, and prior negative figures highlight potential issues in managing cash effectively. Improvement in free cash flow is notable but needs sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.84M	45.23M	54.22M	94.59M	56.34M
Gross Profit	14.91M	25.16M	34.83M	71.31M	37.57M
EBITDA	-27.22M	-15.79M	-27.10M	-2.89M	-102.72M
Net Income	-34.24M	-15.48M	-38.45M	-22.12M	-110.03M
Balance Sheet
Total Assets	260.93M	302.95M	333.55M	376.40M	381.30M
Cash, Cash Equivalents and Short-Term Investments	27.05M	26.73M	31.60M	77.89M	71.08M
Total Debt	40.93M	45.91M	51.13M	59.66M	55.06M
Total Liabilities	84.98M	87.77M	91.52M	92.35M	83.91M
Stockholders Equity	194.68M	230.26M	224.30M	256.25M	267.53M
Cash Flow
Free Cash Flow	10.67M	4.51M	-31.71M	14.86M	49.20M
Operating Cash Flow	10.69M	5.10M	-30.36M	16.32M	49.54M
Investing Cash Flow	-3.00K	364.00K	-1.23M	-1.42M	-11.22M
Financing Cash Flow	-10.85M	-8.77M	-12.49M	-7.22M	-2.54M

China Tian Yuan Healthcare Group Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.79
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0557, the sentiment is Neutral. The current price of 0.79 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.81, and above the 200-day MA of 0.64, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0557.

China Tian Yuan Healthcare Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$17.07B	6.10	-7.44%	2.88%	11.55%	-28.15%
0557	49 Neutral	HK$315.19M	―	-16.11%	―	-40.65%	-121.13%
0219	46 Neutral	HK$312.08M	―	-4.04%	―	12.86%	-297.41%
0617	44 Neutral	HK$334.38M	―	-18.37%	―	-2.69%	-53.59%
0199	44 Neutral	HK$198.68M	―	-31.95%	―	-70.49%	-129.16%
0355	43 Neutral	HK$207.20M	―	-17.37%	―	-3.54%	-49.42%
0078	35 Underperform	€539.27M	―	-36.48%	―	1.87%	-42.24%

China Tian Yuan Healthcare Group Limited Corporate Events

China Tian Yuan Healthcare Group Announces Capital Injections and Shareholder Loan

China Tian Yuan Healthcare Group Limited announced capital injections and a shareholder loan involving its subsidiaries, Hengqin Hanyuemei and Shanghai Rifu, and a third party, Shanghai Huaman. The capital injections will increase Shanghai Rifu’s registered capital significantly, while the shareholder loan will provide additional financial support. These transactions, which are part of a series of agreements with Shanghai Huaman, are subject to disclosure requirements under Hong Kong’s listing rules due to their size.

China Tian Yuan Healthcare Group Secures Unanimous Shareholder Approval at AGM

China Tian Yuan Healthcare Group Limited announced that all resolutions proposed at their Annual General Meeting on June 27, 2025, were unanimously approved by shareholders. These resolutions included the re-election of directors, authorization of directors’ remuneration, reappointment of auditors, and granting of general mandates for issuing and repurchasing shares, indicating strong shareholder support and stability in the company’s governance and operational strategies.

China Tian Yuan Healthcare Group Announces 36th Annual General Meeting

China Tian Yuan Healthcare Group Limited has announced its thirty-sixth annual general meeting to be held on June 27, 2025, in Hong Kong. Key agenda items include the re-election of directors, approval of directors’ remuneration, and the re-appointment of auditors. Additionally, the company seeks approval to allot and issue additional shares, which could impact its capital structure and shareholder value.